Relative Contribution of Lipids and Apolipoproteins to Incident Coronary Heart Disease and Ischemic Stroke: The PRIME StudyCanouï-Poitrine F.a, b · Luc G.c · Bard J.-M.d · Ferrieres J.e · Yarnell J.j · Arveiler D.f · Morange P.g · Kee F.j · Evans A.j · Amouyel P.h · Ducimetiere P.i · Empana J.-P.a
aINSERM, U970, Paris Cardiovascular Research Center, Université Paris Descartes, UMR-S970, Paris, bHospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Université Lyon 1, Lyon, cDepartment of Atherosclerosis, INSERM, U545, Institut Pasteur de Lille, Lille 2 University, Lille, dFaculté de Pharmacie, Université de Nantes, Nantes, eThe Toulouse MONICA Project, INSERM, U558, Département d’Epidémiologie, Université Paul Sabatier, Toulouse, fThe Strasbourg MONICA Project, Laboratoire d’Epidémiologie et de Santé Publique, EA 3430, and Université de Strasbourg, Strasbourg, gINSERM, U626, Laboratory of Hematology, La Timone Hospital, Marseille, hThe Lille MONICA Project, INSERM, U744, Institut Pasteur de Lille, Université Lille Nord de France, Lille, and iINSERM, Université Paris Sud-XI, Paris, France; jThe UKCRC Center of Excellence for Public Health, The Queen’s University, Belfast, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Aim: To compare within the same cohort the association of a large panel of lipids with the risk of incident coronary heart disease (CHD) and ischemic stroke events in participants of the Prospective Epidemiological Study of Myocardial Infarction. Methods: In this binational (Northern Ireland and France) prospective cohort, we considered 9,711 men aged 50–59 years free of CHD and stroke at baseline (1991–1993). The hazard ratios of each lipid marker for CHD and ischemic stroke events were estimated in separate Cox proportional hazard models adjusted for age, study center, systolic blood pressure, antihypertensive treatment, current smoking status, body mass index and diabetes. Results: After 10 years of follow-up, 635 men had a first CHD and 98 a first ischemic stroke event. Total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C, triglycerides, apolipoprotein (Apo) A1 and Apo B100, their ratios and lipoprotein (a) [Lp(a)] were all significantly predictive of future CHD. Associations with ischemic stroke followed the same trend as for CHD, but with lower strength, and none were statistically significant. However, none of the differences between the hazard ratios for CHD and for ischemic stroke were statistically significant. Conclusions: In healthy, middle-aged men, total-C, HDL-C, LDL-C, non-HDL-C, triglycerides, Apo A1 and Apo B100, their ratios and Lp(a) are, if anything, weak predictors of ischemic stroke events over a 10-year period.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.